Speakers
UFSC
Department of Pharmacology - Federal University of Santa Catarina
Title: State of the art of nucleic acid therapy in oncology: evidence and challenges.
Biomanguinhos
PUCRS
Institution: Pontifical Catholic University of Rio de Janeiro
Lecture Title: Rational Design of Inhibitors and Silencers of Cancer-Associated Genes Using Artificial Intelligence
Powell Gene Therapy Center at the University of Florida
MD Anderson Cancer Center
Einstein Hospital Israelita
FMRP-USP
Patient outcomes (efficacy, toxicity – CRS/ICANS)
Manufacturing/logistics challenges
Access barriers in Latin America
Lessons learned from clinical practice
UNICAMP
CEO Gemma Biotherapeutics and Franklin Biolabs
UFRGS
MD Anderson Cancer Center
Senior research, University of Antwerp, Belgica
Johns Hopkins University
MD, JD, LLM (Associate Professor of Medicine and Physiology)
FMRP-USP
Rationale for NK vs T cells
CD33 as a target (AML context)
Advantages: lower toxicity, off-the-shelf potential
Einstein Hospital Israelita
Researcher at the Albert Einstein Israelite Institute for Education and Research.
UFRGS
FMRP-USP
Concept of immune reset (e.g., CAR-T targeting B cells)
Clinical results (e.g., lupus, multiple sclerosis)
Differences vs oncology: lower cell dose, different endpoints (remission vs cytotoxicity)
Safety considerations
Biomanguinhos
Head of RNA Products Development - Biomanguinhos
UFMG
Federal University of Minas Gerais (UFMG)
Title: Cancer immunotherapy based on lipid nanoparticles for nucleic acid delivery
Instituto D'Or
USP
Instituto D'Or
Research Fellow Promega, IDOR and UFRJ (Ttle: Development of non-destructive methods to advance NAMs and organoid research)
Fiocruz
UNICAMP
Professor of Human Anatomy at the State University of Campinas (UNICAMP)
Johns Hopkins University
Regulations for submitting abstracts to Cel-Gen 2026
All abstracts must be written in English, and abstracts selected for oral presentation must also be presented in English.
Submission opening and closing date/time:
Opening: June 1st
Closing: June 30, 12:00 a.m. (midnight) Postponed to August 02, 12:00 a.m. (midnight)
Maximum number of abstracts per author: 3 abstracts
Maximum number of authors per abstract: 15 authors
Title length limit: 250 characters (including spaces)
Abstract length limit: Abstracts are limited to 3,000 characters, including punctuation and spaces (excluding title, authors, and affiliations)
Authors may submit abstracts before completing registration/payment. Registration fees will only be required after abstract acceptance.
Evaluation score/rating scale: up to 6 points
Work presentation formats: Poster and Oral Presentation
Categories:
Questions: contact@abtcelgen.org.br; temalivre3@mezclaeventos.com.br